Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2016

Open Access 01-12-2016 | Research article

The effect of lifestyle intervention in obesity on the soluble form of activated leukocyte cell adhesion molecule

Authors: Alba Sulaj, Johanna Zemva, Ulrike Zech, Annika Woehning, Maik Brune, Gottfried Rudofsky, Peter P. Nawroth, Thomas Fleming, Rüdiger von Bauer

Published in: BMC Endocrine Disorders | Issue 1/2016

Login to get access

Abstract

Background

The aim of this study was to investigate the effect of a lifestyle intervention in obesity on the soluble form of the activated leukocyte cell adhesion molecule (sALCAM) and its association with metabolic parameters.

Methods

Twenty-nine obese subjects selected from the OPTIFAST®52 program. This program consisted into 2 crucial phases: an initial 12-week active weight reduction phase, followed by a 40-week weight maintenance phase. At baseline, after 12 weeks and at the end of the program, fasting glucose and insulin, total cholesterol, LDL-C, HDL-C, triglycerides, adiponectin, leptin, high sensitivity CRP, sALCAM, homeostasis model assessment-estimated insulin resistance (HOMA-IR) and leptin-to-adiponectin-ratio were determined. Oral glucose tolerance test (OGTT) was performed when indicated.

Results

At baseline, the serum concentration of sALCAM was increased and correlated positively with HOMA-IR and negatively with age. At the end of the program, sALCAM concentrations decreased significantly. Multivariate analysis showed that sALCAM significantly correlated with age, glucose concentration after 2 h OGTT and the HOMA-IR. A higher decrease of HOMA-IR during the study was observed in subjects with higher concentration of sALCAM at baseline.

Conclusions

sALCAM might be a novel biomarker in obesity that correlates and predicts insulin sensitivity improvement and that can be affected by lifestyle intervention.
Literature
1.
go back to reference WHO. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894(i-xii):1–253. WHO. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894(i-xii):1–253.
2.
go back to reference Khodabandeloo H., Gorgani-Firuzjaee S., Panahi S. and Meshkani R. Molecular and cellular mechanisms linking inflammation to insulin resistance and β-cell dysfunction. Transl Res. 2015. doi:10.1016/j.trsl.2015.08.011. Khodabandeloo H., Gorgani-Firuzjaee S., Panahi S. and Meshkani R. Molecular and cellular mechanisms linking inflammation to insulin resistance and β-cell dysfunction. Transl Res. 2015. doi:10.​1016/​j.​trsl.​2015.​08.​011.
3.
go back to reference von Bauer R, Oikonomou D, Sulaj A, Mohammed S, Hotz-Wagenblatt A, Gröne HJ, Arnold B, Falk C, Luethje D, Erhardt A, Stern DM, Bierhaus A, Nawroth PP. CD166/ALCAM mediates proinflammatory effects of S100B in delayed type hypersensitivity. J Immunol. 2013;191(1):369–77.CrossRef von Bauer R, Oikonomou D, Sulaj A, Mohammed S, Hotz-Wagenblatt A, Gröne HJ, Arnold B, Falk C, Luethje D, Erhardt A, Stern DM, Bierhaus A, Nawroth PP. CD166/ALCAM mediates proinflammatory effects of S100B in delayed type hypersensitivity. J Immunol. 2013;191(1):369–77.CrossRef
4.
go back to reference Hagen I, Schulte DM, Müller N, Martinsen J, Türk K, Hedderich J, Schreiber S, Laudes M. Soluble receptor for advanced glycation end products as a potential biomarker to predict weight loss and improvement of insulin sensitivity by a very low calorie diet of obese human subjects. Cytokine. 2015;73(2):265–9.CrossRefPubMed Hagen I, Schulte DM, Müller N, Martinsen J, Türk K, Hedderich J, Schreiber S, Laudes M. Soluble receptor for advanced glycation end products as a potential biomarker to predict weight loss and improvement of insulin sensitivity by a very low calorie diet of obese human subjects. Cytokine. 2015;73(2):265–9.CrossRefPubMed
5.
go back to reference Carbotti G, Orengo AM, Mezzanzanica D, Bagnoli M, Brizzolara A, Emionite L, Puppo A, Centurioni MG, Bruzzone M, Marroni P, Rossello A, Canevari S, Ferrini S, Fabbi M. Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors. Int J Cancer. 2013;132(11):2597–605.CrossRefPubMed Carbotti G, Orengo AM, Mezzanzanica D, Bagnoli M, Brizzolara A, Emionite L, Puppo A, Centurioni MG, Bruzzone M, Marroni P, Rossello A, Canevari S, Ferrini S, Fabbi M. Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors. Int J Cancer. 2013;132(11):2597–605.CrossRefPubMed
6.
go back to reference Witzel I, Schröder C, Müller V, Zander H, Tachezy M, Ihnen M, Jänicke F, Milde-Langosch K. Detection of activated leukocyte cell adhesion molecule in the serum of breast cancer patients and implications for prognosis. Oncology. 2012;82(6):305–12.CrossRefPubMed Witzel I, Schröder C, Müller V, Zander H, Tachezy M, Ihnen M, Jänicke F, Milde-Langosch K. Detection of activated leukocyte cell adhesion molecule in the serum of breast cancer patients and implications for prognosis. Oncology. 2012;82(6):305–12.CrossRefPubMed
7.
go back to reference Hansen AG, Arnold SA, Jiang M, Palmer TD, Ketova T, Merkel A, Pickup M, Samaras S, Shyr Y, Moses HL, Hayward SW, Sterling JA, Zijlstra A. ALCAM/CD166 is a TGF-β-responsive marker and functional regulator of prostate cancer metastasis to bone. Cancer Res. 2014;74(5):1404–15.CrossRefPubMedPubMedCentral Hansen AG, Arnold SA, Jiang M, Palmer TD, Ketova T, Merkel A, Pickup M, Samaras S, Shyr Y, Moses HL, Hayward SW, Sterling JA, Zijlstra A. ALCAM/CD166 is a TGF-β-responsive marker and functional regulator of prostate cancer metastasis to bone. Cancer Res. 2014;74(5):1404–15.CrossRefPubMedPubMedCentral
8.
go back to reference Guerraty MA, Grant GR, Karanian JW, Chiesa OA, Pritchard WF, Davies PF. Side-specific expression of activated leukocyte adhesion molecule (ALCAM; CD166) in pathosusceptible regions of swine aortic valve endothelium. J Heart Valve Dis. 2011;20(2):165–7.PubMedPubMedCentral Guerraty MA, Grant GR, Karanian JW, Chiesa OA, Pritchard WF, Davies PF. Side-specific expression of activated leukocyte adhesion molecule (ALCAM; CD166) in pathosusceptible regions of swine aortic valve endothelium. J Heart Valve Dis. 2011;20(2):165–7.PubMedPubMedCentral
9.
go back to reference Ikeda K, Quertermous T. Molecular isolation and characterization of a soluble isoform of activated leukocyte cell adhesion molecule that modulates endothelial cell function. J Biol Chem. 2004;279(53):55315–23.CrossRefPubMed Ikeda K, Quertermous T. Molecular isolation and characterization of a soluble isoform of activated leukocyte cell adhesion molecule that modulates endothelial cell function. J Biol Chem. 2004;279(53):55315–23.CrossRefPubMed
10.
go back to reference Wallmeier D, Winkler JK, Fleming T, Woehning A, Huennemeyer K, Roeder E, Nawroth PP, Friederich HC, Wolfrum C, Schultz JH, Rudofsky G. Genetic modulation of the serotonergic pathway: influence on weight reduction and weight maintenance. Genes Nutr. 2013;8(6):601–10.CrossRefPubMedCentral Wallmeier D, Winkler JK, Fleming T, Woehning A, Huennemeyer K, Roeder E, Nawroth PP, Friederich HC, Wolfrum C, Schultz JH, Rudofsky G. Genetic modulation of the serotonergic pathway: influence on weight reduction and weight maintenance. Genes Nutr. 2013;8(6):601–10.CrossRefPubMedCentral
11.
go back to reference American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care. 2014;37(1):S14–80.CrossRef American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care. 2014;37(1):S14–80.CrossRef
12.
go back to reference Esteghamati A, Ashraf H, Esteghamati AR, Meysamie A, Khalilzadeh O, Nakhjavani M, Abbasi M. Optimal threshold of homeostasis model assessment for insulin resistance in an Iranian population: the implication of metabolic syndrome to detect insulin resistance. Diabetes Res Clin Pract. 2009;84(3):279–87.CrossRefPubMed Esteghamati A, Ashraf H, Esteghamati AR, Meysamie A, Khalilzadeh O, Nakhjavani M, Abbasi M. Optimal threshold of homeostasis model assessment for insulin resistance in an Iranian population: the implication of metabolic syndrome to detect insulin resistance. Diabetes Res Clin Pract. 2009;84(3):279–87.CrossRefPubMed
13.
go back to reference Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, Staiger H, Maerker E, Häring H, Stumvoll M. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes. 2003;52(2):239–43.CrossRefPubMed Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, Staiger H, Maerker E, Häring H, Stumvoll M. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes. 2003;52(2):239–43.CrossRefPubMed
14.
go back to reference Finucane FM, Luan J, Wareham NJ, Sharp SJ, O'Rahilly S, Balkau B, Flyvbjerg A, Walker M, Højlund K, Nolan JJ, Savage DB. European Group for the Study of Insulin Resistance: Relationship between Insulin Sensitivity and Cardiovascular Disease Risk Study Group) Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia. 2009;52(11):2345–9.CrossRefPubMedPubMedCentral Finucane FM, Luan J, Wareham NJ, Sharp SJ, O'Rahilly S, Balkau B, Flyvbjerg A, Walker M, Højlund K, Nolan JJ, Savage DB. European Group for the Study of Insulin Resistance: Relationship between Insulin Sensitivity and Cardiovascular Disease Risk Study Group) Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia. 2009;52(11):2345–9.CrossRefPubMedPubMedCentral
15.
go back to reference Winkler JK, Schultz JH, Woehning A, Piel D, Gartner L, Hildebrand M, Roeder E, Nawroth PP, Wolfrum C, Rudofsky G. Effectiveness of a low-calorie weight loss program in moderately and severely obese patients. Obes Facts. 2013;6(5):469–80.CrossRefPubMed Winkler JK, Schultz JH, Woehning A, Piel D, Gartner L, Hildebrand M, Roeder E, Nawroth PP, Wolfrum C, Rudofsky G. Effectiveness of a low-calorie weight loss program in moderately and severely obese patients. Obes Facts. 2013;6(5):469–80.CrossRefPubMed
16.
go back to reference Klöting N, Fasshauer M, Dietrich A, Kovacs P, Schön MR, Kern M, Stumvoll M, Blüher M. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab. 2010;299(3):E506–15.CrossRefPubMed Klöting N, Fasshauer M, Dietrich A, Kovacs P, Schön MR, Kern M, Stumvoll M, Blüher M. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab. 2010;299(3):E506–15.CrossRefPubMed
17.
go back to reference Twig G, Afek A, Derazne E, Tzur D, Cukierman-Yaffe T, Gerstein HC, Tirosh A. Diabetes risk among overweight and obese metabolically healthy young adults. Diabetes Care. 2014;37(11):2989–95.CrossRefPubMed Twig G, Afek A, Derazne E, Tzur D, Cukierman-Yaffe T, Gerstein HC, Tirosh A. Diabetes risk among overweight and obese metabolically healthy young adults. Diabetes Care. 2014;37(11):2989–95.CrossRefPubMed
18.
go back to reference Scott RA, Fall T, Pasko D, Barker A, Sharp SJ, Arriola L, Balkau B, Barricarte A, Barroso I, Boeing H, Clavel-Chapelon F, Crowe FL, Dekker JM, Fagherazzi G, Ferrannini E, Forouhi NG, Franks PW, Gavrila D, Giedraitis V, Grioni S, Groop LC, Kaaks R, Key TJ, Kühn T, Lotta LA, Nilsson PM, Overvad K, Palli D, Panico S, Quirós JR, Rolandsson O, Roswall N, Sacerdote C, Sala N, Sánchez MJ, Schulze M, Siddiq A, Slimani N, Sluijs I, Spijkerman AM, Tjonneland A, Tumino R, van Der ADL, Yaghootkar H, RISC Study Group; EPIC-InterAct Consortium, McCarthy MI, Semple RK, Riboli E, Walker M, Ingelsson E, Frayling TM, Savage DB, Langenberg C, Wareham NJ. Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independent of obesity. Diabetes. 2014;63(12):4378–87.CrossRefPubMedPubMedCentral Scott RA, Fall T, Pasko D, Barker A, Sharp SJ, Arriola L, Balkau B, Barricarte A, Barroso I, Boeing H, Clavel-Chapelon F, Crowe FL, Dekker JM, Fagherazzi G, Ferrannini E, Forouhi NG, Franks PW, Gavrila D, Giedraitis V, Grioni S, Groop LC, Kaaks R, Key TJ, Kühn T, Lotta LA, Nilsson PM, Overvad K, Palli D, Panico S, Quirós JR, Rolandsson O, Roswall N, Sacerdote C, Sala N, Sánchez MJ, Schulze M, Siddiq A, Slimani N, Sluijs I, Spijkerman AM, Tjonneland A, Tumino R, van Der ADL, Yaghootkar H, RISC Study Group; EPIC-InterAct Consortium, McCarthy MI, Semple RK, Riboli E, Walker M, Ingelsson E, Frayling TM, Savage DB, Langenberg C, Wareham NJ. Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independent of obesity. Diabetes. 2014;63(12):4378–87.CrossRefPubMedPubMedCentral
19.
go back to reference Vogeser M, König D, Frey I, Predel HG, Parhofer KG, Berg A. Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle interventions in obese persons. Clin Biochem. 2007;40(13–14):964–8.CrossRefPubMed Vogeser M, König D, Frey I, Predel HG, Parhofer KG, Berg A. Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle interventions in obese persons. Clin Biochem. 2007;40(13–14):964–8.CrossRefPubMed
20.
go back to reference Preciado-Puga MC, Malacara JM, Fajardo-Araujo ME, Wröbel K, Wröbel K, Kornhauser-Araujo C, Garay-Sevilla ME. Markers of the progression of complications in patients with type 2 diabetes: a one-year longitudinal study. Exp Clin Endocrinol Diabetes. 2014;122(8):484–90.CrossRefPubMed Preciado-Puga MC, Malacara JM, Fajardo-Araujo ME, Wröbel K, Wröbel K, Kornhauser-Araujo C, Garay-Sevilla ME. Markers of the progression of complications in patients with type 2 diabetes: a one-year longitudinal study. Exp Clin Endocrinol Diabetes. 2014;122(8):484–90.CrossRefPubMed
21.
go back to reference Chadderdon SM, Belcik JT, Bader L, Kirigiti MA, Peters DM, Kievit P, Grove KL, Lindner JR. Proinflammatory endothelial activation detected by molecular imaging in obese nonhuman primates coincides with onset of insulin resistance and progressively increases with duration of insulin resistance. Circulation. 2014;129(4):471–8.CrossRefPubMed Chadderdon SM, Belcik JT, Bader L, Kirigiti MA, Peters DM, Kievit P, Grove KL, Lindner JR. Proinflammatory endothelial activation detected by molecular imaging in obese nonhuman primates coincides with onset of insulin resistance and progressively increases with duration of insulin resistance. Circulation. 2014;129(4):471–8.CrossRefPubMed
22.
go back to reference Karakelides H, Irving BA, Short KR, O'Brien P, Nair KS. Age, obesity, and sex effects on insulin sensitivity and skeletal muscle mitochondrial function. Diabetes. 2010;59(1):89–97.CrossRefPubMed Karakelides H, Irving BA, Short KR, O'Brien P, Nair KS. Age, obesity, and sex effects on insulin sensitivity and skeletal muscle mitochondrial function. Diabetes. 2010;59(1):89–97.CrossRefPubMed
Metadata
Title
The effect of lifestyle intervention in obesity on the soluble form of activated leukocyte cell adhesion molecule
Authors
Alba Sulaj
Johanna Zemva
Ulrike Zech
Annika Woehning
Maik Brune
Gottfried Rudofsky
Peter P. Nawroth
Thomas Fleming
Rüdiger von Bauer
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2016
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-016-0138-2

Other articles of this Issue 1/2016

BMC Endocrine Disorders 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine